GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nirvana Life Sciences Inc (XCNQ:NIRV) » Definitions » Debt-to-EBITDA

Nirvana Life Sciences (XCNQ:NIRV) Debt-to-EBITDA : 0.35 (As of Jan. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Nirvana Life Sciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Nirvana Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$0.02 Mil. Nirvana Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$0.00 Mil. Nirvana Life Sciences's annualized EBITDA for the quarter that ended in Jan. 2024 was C$0.07 Mil. Nirvana Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2024 was 0.35.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Nirvana Life Sciences's Debt-to-EBITDA or its related term are showing as below:

XCNQ:NIRV' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.04   Med: -0.04   Max: 19.06
Current: -0.02

During the past 6 years, the highest Debt-to-EBITDA Ratio of Nirvana Life Sciences was 19.06. The lowest was -1.04. And the median was -0.04.

XCNQ:NIRV's Debt-to-EBITDA is ranked worse than
100% of 277 companies
in the Biotechnology industry
Industry Median: 1.36 vs XCNQ:NIRV: -0.02

Nirvana Life Sciences Debt-to-EBITDA Historical Data

The historical data trend for Nirvana Life Sciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nirvana Life Sciences Debt-to-EBITDA Chart

Nirvana Life Sciences Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Apr22 Apr23
Debt-to-EBITDA
Get a 7-Day Free Trial 19.06 -0.09 - - -0.04

Nirvana Life Sciences Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 -0.02 -0.01 -0.03 0.35

Competitive Comparison of Nirvana Life Sciences's Debt-to-EBITDA

For the Biotechnology subindustry, Nirvana Life Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nirvana Life Sciences's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nirvana Life Sciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Nirvana Life Sciences's Debt-to-EBITDA falls into.



Nirvana Life Sciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Nirvana Life Sciences's Debt-to-EBITDA for the fiscal year that ended in Apr. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.058 + 0) / -1.391
=-0.04

Nirvana Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.024 + 0) / 0.068
=0.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jan. 2024) EBITDA data.


Nirvana Life Sciences  (XCNQ:NIRV) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Nirvana Life Sciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Nirvana Life Sciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Nirvana Life Sciences (XCNQ:NIRV) Business Description

Traded in Other Exchanges
N/A
Address
650 West Georgia Street, Suite 2110, Vancouver, BC, CAN, V6B 4N8
Nirvana Life Sciences Inc is focused on developing medical products and regimens that address addiction. The company is working on novel formulations of psilocybin and other naturally-sourced psychedelics to treat pain, opioid dependency, and other health problems.

Nirvana Life Sciences (XCNQ:NIRV) Headlines

No Headlines